Sandra Horning's shoes to be filled by Levi Garraway at Roche
The big shoes of Sandra Horning (pictured above, with her succesor), chief medical officer and head of global product development at Swiss pharma giant Roche (ROG: SIX), are to be filled by Levi Garraway.
Dr Horning, who will retire at the end of the year, has been credited with bringing 15 new medicines to market during her decade-long stint with Roche and its Genentech unit in areas including cancer, multiple sclerosis, influenza and blindness. She has been in her current role since January 2014.
A company statement paid tribute to her incredible contributions to medicine and her inspirational commitment to science and patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze